The recent article in Current Opinion in Rheumatology describes recent advancements in diagnostic and therapeutic approaches to inclusion body myositis (IBM).
Early diagnosis is key for patients with inclusion body myositis.
Some key points made in this article:
- The Anti-cN-1A (NT5C1A) autoantibody is noted to be potentially useful in the diagnosis of IBM.
- MRI, as well as ultrasound imaging, may be helpful in diagnosing IBM and in monitoring the progress of the disease and in measuring the outcomes of clinical trials.
- Recent small-scale studies of Arimoclomol and Rapamycin have shown promising results and further investigation of these medications is ongoing.
- Exercise is likely to form an increasingly important facet of management of patients with IBM, but the optimal type of exercise program has not yet been determined.
- An important reminder for physicians is to be proactive in enrolling patients in clinical trials for IBM.
- Use of botulinum neurotoxin A injections to treat dysphagia: indicates the rates of aspiration and aspiration pneumonia decreased with injections to indicated throat muscles
Join our email updates and newsletter
Subscribe to our general myositis-related email updates. If you are a member of MSU, you will automatically recieve these updates and there is no need to subscribe here. To register for your free MSU membership and access to The Myositis Community Network, visit UnderstandingMyositis.org/register